Abstract. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.
Introduction
Colorectal cancer is the third most-common cancer in the world with one million new cases diagnosed in 2002, and the number of new cases worldwide has increased rapidly since 1975 (1) . Tumor invasion, regional lymph node metastasis, and distant organ metastasis are important factors for determining colorectal cancer prognosis. Recent molecular studies have elucidated some of the mechanisms and the sequence of tumor progression (2, 3) . It is therefore fundamentally important to identify molecular markers of more aggressive colorectal tumor phenotypes in order to adjust patient's treatment accordingly. However, there is a paucity of molecular predictive indicators for regional disease invasion and metastasis.
Chicken ovalbumin upstream promoter-transcription factors (COUP-TFs) are orphan nuclear receptors (4) . They belong to the steroid/thyroid hormone receptor superfamily of nuclear receptor proteins and are required for regulation of gene expression (5) , development, differentiation, and homeostasis (6) . COUP-TFs bind to cis-acting elements in the target genes either as homodimers or as a heterodimer with retinoid X receptors (RXRs) (7) . There is evidence that COUP-TFs modulate the activity of other nuclear receptors including estrogen receptors, retinoic acid receptors, RXRs, vitamin D3 receptors, thyroid hormone receptors, peroxisome proliferator activated receptors and hepatocyte nuclear factor 4, all of which are involved in cell growth and differentiation (7) (8) (9) . Angiogenesis in COUP-TFII mutant mice is largely impaired (10, 11) , and defects mimic the phenotypes exhibited by mice lacking angiopoietin-1 or its receptor, TIE2. It has also been suggested that COUP-TFII plays an important role in mesenchymal-endothelial interactions (11) . COUP-TFs are expressed in certain tumor cell lines (12) , including human endometrial cancer cells (13) , lung cancer cells (14) , and in adrenal tumors (15) , but are not expressed in terminally differentiated epithelial cells. However, the relationship between COUP-TFII expression and cancer development is not fully understood. A recent study has shown that expression of COUP-TFII enhances invasiveness of human lung carcinoma cells and has suggested that COUP-TFII may be considered as a new The link between COUP-TFII and cancer is suggested by in vitro observation, which shows that the increased expression of COUP-TFII correlated with invasiveness in human lung carcinoma cells (16) . However, there is no report on the biological and clinical significance of COUP-TFII in colorectal cancer patients. In this study, we investigated the expression of COUP-TFII in 95 primary colorectal cancers and compared this value with that of the corresponding normal colorectal tissue, and looked for correlations between the expression of this protein and clinicopathological factors and prognosis in colorectal cancer patients.
Materials and methods
Patients and tissue samples. Ninety-five consecutive colorectal cancer patients who were eligible and received surgery at Dong-A University Hospital from 2002 to 2003 were enrolled in the study. Tissue samples from patients were formalin-fixed and paraffin-embedded. Patients with familial adenomatous polyposis or inflammatory bowel disease, synchronous colorectal or extracolorectal cancers, and those lost to follow-up were excluded. None of the patients had a family history of colorectal cancer. Tumor stage was classified according to Dukes' criteria. Fifty-three patients were classified as Dukes' B, and 42 as Dukes' C. Information concerning age, gender, histologic grade, and stage was retrieved by reviewing the pathology and surgical reports. No patient had received preoperative chemotherapy or radiotherapy. This laboratory study was approved by the Institutional Review Board at Dong-A University Hospital, and written informed consent was obtained.
Immunohistochemistry. Immunohistochemical studies for COUP-TFII were performed on formalin-fixed, paraffinembedded, 4 μm-thick tissue sections using the avidin-biotinperoxidase complex method. The primary antibodies were a mouse monoclonal antibody against COUP-TFII (Perseus Proteomics Inc., Tokyo, Japan) at a 1:1,000 dilution. Deparaffinization of all the sections was performed through a series of xylene baths, and rehydration was performed with a series of graded alcohol solutions. To enhance the immunoreactivity, microwave antigen retrieval was performed at 750 W for 30 min in Tris/EDTA buffer (pH 9.0) for COUP-TFII. After blocking the endogenous peroxidase activity with 5% hydrogen peroxidase for 10 min, primary antibody incubation was performed for 1 h at room temperature. Cap-Plus Biotinylated secondary antibody (Zymed) was applied for 30 min at room temperature and then Cap-Plus Streptavidin-HRP (Zymed) was applied for 30 min at room temperature. After washing the tissue samples in Trisbuffered saline for 10 min, 3, 3'-diaminobenzidine was used as a chromogen, and then Mayer's hematoxylin counterstain was applied.
Immunoreactivities for the COUP-TFII expression were defined by the presence of nuclear staining. Samples were defined as COUP-TFII positive if >5% of the tumor cells showed immunoreactivity. Table I . Correlation between patient characteristics and COUP-TFII expression. 
CEA, carcinoembryonic antigen and COUP-TFII, chicken ovalbumin upstream promoter-transcription factor II. a P value is based on Fisher's exact test.
-
Statistical analysis. The samples were divided into two groups on the basis of positive or negative COUP-TFII staining. The number of samples in each group was compared, as were the clinicopathological variables and patient survival rates. Statistical analysis was performed with Fisher's exact test as a 5% level of significance. Disease-free survival (DFS) was defined as the length of time from surgery to initial disease recurrence. Overall survival (OS) was calculated from the day the surgery was performed to the day of death or the day of the last follow-up. The KaplanMeier method was used for survival analysis, and the statistical significance was analyzed by the log-rank test. Multivariate analysis with covariates showing statistical significance in univariate analysis was performed by the Cox proportional hazards model. A probability level of ≤0.05 was chosen for statistical significance. 
Results

Expression of COUP-TFII in human colorectal cancer
tissues. COUP-TFs are expressed in some tumor cell lines (12) , including human endometrial cancer cells (13) , lung cancer cells (14) , and in adrenal tumors (15) , but are not expressed in terminally differentiated epithelial cells. To investigate whether COUP-TFII is expressed in human colorectal carcinomas, immunohistochemistry was performed using an antibody that recognizes an epitope of COUP-TFII.
No or weak COUP-TFII staining was detected in normal colonic mucosa, whereas moderate to strong COUP-TFII staining was observed in the nuclei of colorectal tumor cells (Fig. 1A and B) . In the present study, positive expression of COUP-TFII was found in 55 (57.89%) of the 95 colorectal carcinoma tissue specimens, in which the immunostaining occurred predominantly in the nuclei of tumor cells. Table II . Three-year DFS and OS according to prognostic factors (univariate analysis). 
Relationship between COUP-TFII expression and clinicopathologic features. The relationship between COUP-TFII
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DFS, disease-free survival; OS, overall survival; CEA, carcinoembryonic antigen; and COUP-TFII, chicken ovalbumin upstream promotertranscription factor II.
a P-value is based on a univariate two-sided log-rank test.
- Table I . No significant correlation was found between COUP-TFII expression and age at the time of surgery, gender, tumor location, histopatholgic grade, lymph node metastasis, or vessel invasion.
----------------------------------------------------------------------------------------------------expression and clinicopathologic features is summarized in
COUP-TFII expression and outcome in colorectal cancer patients.
To determine whether COUP-TFII expression is a significant prognostic factor for the survival of patients with surgically resected colorectal carcinoma, we used a log-rank test with Kaplan-Meier estimates. The median follow-up duration was 29.6 months. Of the 95 patients analyzed, those with COUP-TFII expression (55 cases) had a slightly higher trend of 3-year DFS than those with negative staining (78.1% vs. 67.5%, P=0.1221; Table II ; Fig. 2A ). Patients whose tumors were positive for COUP-TFII expression (55 cases) had a significantly higher 3-year OS than those with negative staining (80.4% vs. 57.7%, P=0.0491; Table II ; Fig.  2B ). These results indicate that the elevated COUP-TFII expression is associated with a better tumor prognosis and suggest that COUP-TFII expression may be a valuable good prognostic marker in colorectal cancer. Multivariate analysis was used to determine the independent prognostic significance of COUP-TFII expression. Nodal involvement and CEA were tested in a Cox proportional hazards model. CEA and COUP-TFII expression were independent prognostic factors (P=0.019 and P=0.024, respectively; Table III ). However, nodal involvement was not an independent prognostic factor for colorectal cancer (P=0.079; Table III ). The role of COUP-TFII in colorectal cancer may be better defined after a longer follow-up period and in a larger sample size. Future prospective studies to evaluate the clinical significance of COUP-TFII expression in colorectal cancer patients are warranted.
Discussion
Although the expression profile of COUP-TFII in several cancer cell lines has been investigated previously (12) (13) (14) (15) , no published data are available on the expression of COUP-TFII and the role of COUP-TFII in colorectal cancer.
Analyzing 95 colorectal cancer patients by immunohistochemistry, we have shown that 57.89% of the colorectal cancer cases in our samples were positive for COUP-TFII expression. We did not detect strong expression of COUP-TFII in the nuclei of normal colorectal mucosa cells (Fig. 1A) . Although studies investigating the expression of COUP-TFII in several cancer cell lines have been reported (12) (13) (14) (15) , the mechanism underlying different expression levels of COUP-TFII in colorectal cancer is currently unknown. Further studies to evaluate the effect of the different levels of COUP-TFII expression in colorectal cancer cell lines are necessary to clarify the target genes and downstream pathways of COUP-TFII activity. In this study, no significant correlation was found between COUP-TFII expression and age at surgery, gender, CEA, size, vessel invasion, tumor location, histopathologic differentiation, or lymph node metastasis (Table I) . We compared the 3-year OS rate between the COUP-TFII negative and COUP-TFII positive expression groups. Patients with COUP-TFII positive tumors (55 cases) had a significantly better 3-year OS rate than those with COUP-TFII negative tumors (80.4% vs. 57.7%, P=0.0491; Table II; Fig. 2B ). In addition, multivariate analysis showed that COUP-TFII expression and CEA were independent prognostic factors for colorectal cancer (Table III) . However, a longer follow-up may be necessary to clarify this point. The reason why the colorectal cancers with positive COUP-TFII expression show better OS is not known. The physiological role of COUP-TFII is currently elucidated. Gene knockout experiments have revealed that COUP-TFII mutants display defects in angiogenesis, vascular remodeling, and fetal heart development (10, 11) . A previous study showed that the expression of COUP-TFII enhanced invasive ability and expression of collagenase type IV (MMP-2) of human lung carcinoma cells. Based on those observations, we expected that the patients with COUP-TFII-positive expression had poorer prognosis than those with COUP-TFII negative expression. However, our data are contradictory to our expectation. The expression of COUP-TFII was not related to vessel invasion or nodal involvement. The reason for the discrepancies between our study and the previous data may result from the different tissues and different cells studied. The findings support our data are as follows. Lin et al have shown that the expression of COUP-TFII plays a role in mediating the growth inhibitory effect of trans-retinoic acid in cancer cells (18) . A previous report demonstrated that the expression of COUP-TFII was reduced in 30% of breast cancer cell lines and the introduction of COUP-TFII to MDA-MB-435 cells resulted in reduced growth and plating efficiency (19) . To investigate the biological function of COUP-TFII, we are planning the following experiments: a) Establishment of the transfectant of the COUP-TFII gene to clarify the effect of proliferation and invasiveness of human colorectal cancer cells. b) Interference of the COUP-TFII gene expression by small interfering RNA to examine the alteration of its proliferation and invasiveness.
Currently, the biologic function and significance of COUP-TFII in various cancers remains unknown. We are investigating the expression and biological significance of COUP-TFII in several cancer tissues, including esophageal 
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Hazard ratio 95% Cl ------------------------------------------------- CEA, carcinoembryonic antigen and COUP-TFII, chicken ovalbumin upstream promoter-transcription factor II. Multivariate analysis retained only statistically significant (P<0.05) prognostic factors in the Cox regression model. Variables tested were node involvement, CEA, and COUP-TFII expression level.
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-------------------------------------------------and gastric cancers. In summary, we have demonstrated COUP-TFII protein expression in colorectal cancers using immunohistochemistry. Positive COUP-TFII protein expression was detected in 57.89% of colorectal cancers in our sample; however, COUP-TFII protein expression did not correlate with any clinicopathological parameters evaluated. The study demonstrated that COUP-TFII is a potential positive prognostic marker. To our knowledge, this is the first study to determine that COUP-TFII protein expression level in primary colorectal cancers is predictive of good prognosis. The molecular classification of COUP-TFII expression in primary colorectal cancers may be useful as an indicator for good prognosis. Additional studies on biological behavior of the colorectal cancers expressing COUP-TFII may allow the development of new targeted therapies to enhance COUP-TFII activity.
